Compare ATKR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATKR | MESO |
|---|---|---|
| Founded | 1959 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2016 | N/A |
| Metric | ATKR | MESO |
|---|---|---|
| Price | $56.33 | $14.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $75.67 | N/A |
| AVG Volume (30 Days) | 243.7K | ★ 259.9K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $2,850,378,000.00 | N/A |
| Revenue This Year | $6.86 | $644.56 |
| Revenue Next Year | $3.94 | $38.70 |
| P/E Ratio | $127.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.92 | $9.61 |
| 52 Week High | $80.06 | $21.50 |
| Indicator | ATKR | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 26.09 | 37.19 |
| Support Level | $55.25 | $14.53 |
| Resistance Level | $66.25 | $16.33 |
| Average True Range (ATR) | 2.00 | 0.57 |
| MACD | -0.75 | -0.05 |
| Stochastic Oscillator | 10.92 | 31.29 |
Atkore Inc is a manufacturer of Electrical products for the non-residential construction and renovation markets, as well as residential markets, and Safety & Infrastructure products for the construction and industrial markets. The Electrical segment manufactures products used in the construction of electrical power systems including conduit, cable, and installation accessories. This segment serves contractors in partnership with the electrical wholesale channel. The Safety & Infrastructure segment designs and manufactures solutions including metal framing, mechanical pipe, perimeter security, and cable management. These solutions are marketed to contractors, original equipment manufacturers (OEMs), and end-users. The majority of revenue is generated from the Electrical segment.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.